Metastatic Colon Cancer Clinical Trial
Official title:
A Randomized Phase Ⅱ Study of XELOX Chemotherapy With or Without Surgery of Primary Lesion for Colon Cancer Patients With Unresectable Metastatic Lesions
The primary endpoint is to evaluate the TFS (time to failure of strategy).
The primary endpoint is to evaluate the time to failure of strategy, that is the second progression time after induction therapy by the use of XELOX regimen, comparing XELOX regimen chemotherapy combined with or without surgical resection of the primary lesion from the time of randomization to maintenance therapy and reapplication of induction therapy, or time to the use of second line strategy (if no reapplication of induction therapy) or time to no further treatment. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04186117 -
Development of Clinical and Biological Database in Colorectal Cancer
|
N/A | |
| Completed |
NCT05468892 -
Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial
|
Phase 2 | |
| Active, not recruiting |
NCT00986661 -
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
|
Phase 1 | |
| Completed |
NCT03176485 -
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
|
N/A | |
| Recruiting |
NCT05983367 -
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT03730558 -
ZETA : Prospective Observational Study
|
||
| Recruiting |
NCT06180460 -
CALM: Managing Distress in Malignant Brain Cancer
|
N/A | |
| Active, not recruiting |
NCT03251378 -
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04737213 -
SGM-101 in Colorectal Lung Metastases
|
Phase 2 | |
| Recruiting |
NCT05714124 -
Liver Embolization Approaches for Tumor Management
|
||
| Recruiting |
NCT05396807 -
REVERT - taRgeted thErapy for adVanced colorEctal canceR paTients
|
N/A | |
| Active, not recruiting |
NCT02724202 -
Curcumin in Combination With 5FU for Colon Cancer
|
Early Phase 1 | |
| Withdrawn |
NCT03764137 -
Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05848739 -
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06202183 -
Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial
|
N/A | |
| Withdrawn |
NCT01936961 -
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors
|
N/A | |
| Not yet recruiting |
NCT06358677 -
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Metastatic Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT03415126 -
A Study of ASN007 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02834052 -
Pembrolizumab + Poly-ICLC in MRP Colon Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06446557 -
De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer
|
Phase 3 |